Cancer Immunology Research

Papers
(The TQCC of Cancer Immunology Research is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)
ArticleCitations
A Sampling of Highlights from the Literature210
Optimal Neoantigen Cancer Vaccines Target CD8+ and CD4+ T Cells with Multiple Antigens140
Abstract P003: Efficacy results of a novel vaccine composed of stimulated and haptenized tumors cells in Balbc mice grafted with murine colon adenocarcinoma CT26 cells130
Abstract P039: The immune profile of colorectal and pancreas adenocarcinomas: Differences between central and peripheric tumor regions107
Correction: Inflammation Mediated by Gut Microbiome Promotes Immune Suppression and Lung Adenocarcinoma Progression97
Transforming the Dark into Light: A Siglec-9 Switch91
Abstract A022: Therapeutic inhibition of TREX1 elicits type I interferon–mediated antitumor immunity with minimal autoimmune toxicity90
Abstract A018: Targeting PTPN1/PTPN2 with KQ-791 enhances NK cell cytotoxicity during tumor rechallenge82
Abstract PR-10: Leveraging peripheral leukocyte recruitment to improve efficacy and mitigate toxicities following checkpoint blockade73
Abstract B002: Meta-Analysis of Neoantigens: Insights from the Cancer Epitope Database and Analysis Resource (CEDAR)73
IL18 at the Crossroads between Chronic Inflammation and T-cell Exhaustion in Pancreatic Cancer71
T-cell Senescence in the Tumor Microenvironment70
Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer67
Single-Cell Analysis of Posttranslational Modifications Identifies Immunosuppressive Macrophage Subtypes in the HBV-Positive Hepatocellular Carcinoma Microenvironment66
IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8+ T cells Infiltrating Pancreatic Ductal Adenocarcinoma63
Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer63
Exercise as an Immune Boost: Mechanism-Driven Support for Lifestyle Interventions61
The ω-3 Polyunsaturated Fatty Acid Docosahexaenoic Acid Enhances NK-Cell Antitumor Effector Functions61
A Population of TIM4+FOLR2+ Macrophages Localized in Tertiary Lymphoid Structures Correlates to an Active Immune Infiltrate Across Several Cancer Types59
Host Interactions with Engineered T-cell Micropharmacies58
Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy58
Preclinical Characterization and Phase I Study of an Anti–HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies57
Reciprocal Interactions Between the Gut Microbiome and Mammary Tissue Mast Cells Promote Metastatic Dissemination of HR+ Breast Tumors54
CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity53
A Sampling of Highlights from the Literature52
Abstract P073: Gut microbiota shift in melanoma patients undergoing immunotherapy is associated with clinical response50
Abstract P009: Correlation between immune modulation of macrophage recruitment and new blood vessel formation in a subcutaneous murine mouse model of colorectal cancer47
Abstract IA17: The power of ONE: Immunology in the age of single cell genomics47
Engineering CD20 CARs with a Twist46
A Sampling of Highlights from the Literature45
Circulating neoantigen- and viral oncoprotein–specific CD8+ T cells share a transcriptional signature44
Ethnicity, Immunity, and Outcomes: Biology versus Socioeconomic Status44
Identification and Phenotypic Characterization of Neoantigen-Specific Cytotoxic CD4+ T Cells in Endometrial Cancer43
Profiling Multiple CD8+ T-cell Functional Dimensions Enhances Breast Cancer Immune Assessment43
Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS–STING Pathway in Triple-Negative Breast Cancer Cells43
The HSP90 Inhibitor Pimitespib Targets Regulatory T Cells in the Tumor Microenvironment42
Loss of LRRC33-Dependent TGFβ1 Activation Enhances Antitumor Immunity and Checkpoint Blockade Therapy41
High Mobility Group Protein B1 Decreases Surface Localization of PD-1 to Augment T-cell Activation41
Sensory Nerves Impede the Formation of Tertiary Lymphoid Structures and Development of Protective Antimelanoma Immune Responses41
Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity41
Harnessing Microbiota to Improve Immunotherapy for Gastrointestinal Cancers39
KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in Ovarian Cancer39
The SETDB1–TRIM28 Complex Suppresses Antitumor Immunity38
Low TCR Binding Strength Results in Increased Progenitor-like CD8+ Tumor-Infiltrating Lymphocytes38
High Expression of MHC Class I Overcomes Cancer Immunotherapy Resistance Due to IFNγ Signaling Pathway Defects37
Evaluation of Proton Minibeam Radiotherapy on Antitumor Immune Responses in a Rat Model of Glioblastoma35
Ncoa2 Promotes CD8+ T cell–Mediated Antitumor Immunity by Stimulating T-cell Activation via Upregulation of PGC-1α Critical for Mitochondrial Function35
SPP1+ Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8+ T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma35
Antibody-Mediated Inhibition of HLA/LILR Interactions Breaks Innate Immune Tolerance and Induces Antitumor Immunity35
Abstract P027: Extending intratumoral therapeutic durability using a multivalent immunotherapy platform34
Fueling T-cell Antitumor Immunity: Amino Acid Metabolism Revisited34
A Sampling of Highlights from the Literature33
The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission33
About the Rising Star33
Abstract P011: B cell subsets that correlate with anti-PD-1 resistance in a preclinical model of HPV+ oropharyngeal cancer33
Navigating Critical Challenges Associated with Immunopeptidomics-Based Detection of Proteasomal Spliced Peptide Candidates32
Abstract A012: Cancer acquires therapy resistance by converting immune infiltration to exclusion through NK cell-macrophage interactions32
In Vivo Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade31
Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma30
CCRL2 Expression by Specialized Lung Capillary Endothelial Cells Controls NK-cell Homing in Lung Cancer30
Tumor-Associated CD19+CD39− B Regulatory Cells Deregulate Class-Switch Recombination to Suppress Antibody Responses30
PRDX-1 Supports the Survival and Antitumor Activity of Primary and CAR-Modified NK Cells under Oxidative Stress29
Setdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma29
Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry29
PIKfyve Inhibition Induces Antitumor Immunogenicity by Attenuating STING Trafficking and Lysosomal Degradation28
Denosumab Enhances Antitumor Immunity by Suppressing SPP1 and Boosting Cytotoxic T Cells28
TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer28
Abstract IA07: Impact of immunotherapy on COVID-19 immunity: Insights from checkpoint blockade in cancer28
Spatial Organization of Macrophages in CTL-Rich Hepatocellular Carcinoma Influences CTL Antitumor Activity28
A Sampling of Highlights from the Literature27
Abstract IA12: Cancer evolution: Chromosomal instability and immune evasion27
A Sampling of Highlights from the Literature27
Abstract P054: Immune determinants of the association between tumor mutational burden and immunotherapy response across cancer types27
Battle Within the Sexes: Differences in Male and Female Immunity and the Impact on Antitumor Responses26
Coexisting Alterations of MHC Class I Antigen Presentation and IFNγ Signaling Mediate Acquired Resistance of Melanoma to Post–PD-1 Immunotherapy26
CAR T-cell Entry into Tumor Islets Is a Two-Step Process Dependent on IFNγ and ICAM-126
NKG7 Is a T-cell–Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy25
Intratumoral TREX1 Induction Promotes Immune Evasion by Limiting Type I IFN25
CXCL10 Recruitment of γδ T Cells into the Hypoxic Bone Marrow Environment Leads to IL17 Expression and Multiple Myeloma Progression25
Abstract PR-05: Sumoylation blockade exposes the dark epigenome to drive ZBP1 viral mimicry for cancer immunotherapy25
Increased CaMKK2 Expression Is an Adaptive Response That Maintains the Fitness of Tumor-Infiltrating Natural Killer Cells25
Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies24
Determinants for Antitumor and Protumor Effects of Programmed Cell Death24
Atypical B Cells Promote Cancer Progression and Poor Response to Bacillus Calmette-Guérin in Non–Muscle Invasive Bladder Cancer24
Reprogramming CD8+ T-cell Branched N- Glycosylation Limits Exhaustion, Enhancing Cytotoxicity and Tumor Killing24
Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors23
Translating Science into Survival: Report on the Seventh International Cancer Immunotherapy Conference23
Targeting LxCxE Cleft Pocket of Retinoblastoma Protein in Immunosuppressive Macrophages Inhibits Ovarian Cancer Progression23
Autoantibodies Drive Heart Damage Caused by Concomitant Radiation and PD-1 Blockade23
IGM-7354, an Immunocytokine with IL15 Fused to an Anti–PD-L1 IgM, Induces NK and CD8+ T cell–Mediated Cytotoxicity of PD-L1–Positive Tumor Cells23
The E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling23
CD8+ T Cells Keep Their (K+)urrency for Function22
A Sampling of Highlights from the Literature22
A Sampling of Highlights from the Literature22
Cancer Immunology Research: A Decade of Illumination and Innovation21
Pan-cancer single-cell RNA sequencing analysis refines multi-origin monocyte and macrophage lineages21
A Metabolic Axis of Immune Intractability21
MerTK Induces Dysfunctional Dendritic Cells by Metabolic Reprogramming21
Abstract B011: Mast cells mediate tumor-suppressive effects in head and neck cancer through immune-microenvironmental regulation20
Antitumor Immune Responses in B2M -Deficient Cancers20
Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic Cells20
Abstract P075: NTX-1088, a potent first-in-class, anti-PVR mAb, restores expression and function of DNAM1 for optimal DNAM1-mediated antitumor immunity20
Combination CXCR4 and PD-1 Blockade Enhances Intratumoral Dendritic Cell Activation and Immune Responses Against Hepatocellular Carcinoma20
CAR Binders Affect CAR T-cell Tonic Signaling, Durability, and Sensitivity to Target20
Single-Cell Clonal Lineage Tracing Identifies the Transcriptional Program Controlling the Cell-Fate Decisions by Neoantigen-Specific CD8+ T Cells20
About the Rising Star20
Adenosine-Deaminase-Acting-on-RNA-1 Facilitates T-cell Migration toward Human Melanoma Cells20
Abstract B003: Oncolytic VSVd51-LIGHT and folfirinox chemotherapy increases anti-tumor immune response in pancreatic ductal adenocarcinoma20
Regulatory Considerations for Genome-Edited T-cell Therapies20
Abstract IA20: What does not kill it makes it stronger: Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy20
A Sampling of Highlights from the Literature20
A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors19
Targeting SALL4 with an HLA Class I–restricted TCR for cancer immunotherapy19
A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors19
The PO4-tential for Less Toxic CAR T-cell Therapies19
Immunogenetic Metabolomics Reveals Key Enzymes That Modulate CAR T-cell Metabolism and Function18
HER2Δ16 Engages ENPP1 to Promote an Immune-Cold Microenvironment in Breast Cancer18
Abstract B022: Investigating Biased GPCRs Activation by Nutraceutical Caffeine and Nicotine in Transactivating Glycosylated Receptors to Induce EMT in Cancer Metastasis18
Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy18
Glioblastoma Cell–Derived lncRNA-Containing Exosomes Induce Microglia to Produce Complement C5, Promoting Chemotherapy Resistance18
The Pellino1–PKCθ Signaling Axis Is an Essential Target for Improving Antitumor CD8+ T-lymphocyte Function18
The Immunopeptidome from a Genomic Perspective: Establishing the Noncanonical Landscape of MHC Class I–Associated Peptides18
Abstract IA03: Therapeutic modulation of nucleic acids-induced immune activation18
M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation17
The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Effi17
A “Function-First” Approach to Identify Regulatory T cell–Targeting Antibodies for Immunotherapy17
Identification of Core Techniques That Enhance Genome Editing of Human T Cells Expressing Synthetic Antigen Receptors17
Abstract IA06: Chimeric antigen receptor macrophages for the treatment of solid tumors17
A Sampling of Highlights from the Literature17
Abstract P057: Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas17
TLR5 Signaling Causes Dendritic Cell Dysfunction and Orchestrates Failure of Immune Checkpoint Therapy against Ovarian Cancer17
CD206+CD14− Skin-Resident Macrophages and DC–T Cell Clusters Are Spatial Features Characterizing Nonrelapsing Cutaneous Squamous Cell Carcinoma17
Nanobody-Directed CEA-Targeting CAR T Cells Eliminate Gastrointestinal Cancer Xenografts17
Abstract P070: The safety and efficacy of Durvalumab and Paclitaxel combination in metastatic triple-negative breast cancer: An open-label phase I/II trial with 2-years follow-up16
Abstract IA04: Reprogramming the tumor–immune microenvironment: From stromal circuits to engineered microbial immunotherapies16
CD49a Targeting Enhances NK Cell Function and Antitumor Immunity16
Allogeneic CAR T Cells: Complex Cellular Therapy Designs Test the Limits of Our Preclinical Models16
Abstract B007: Tissue-Specific B Cell Differentiation Limits Anti-Tumor Efficacy of Radiation and Immunotherapy16
Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells16
CD4+ Regulatory T Cells in Human Cancer: Subsets, Origin, and Molecular Regulation16
Immune Modulation of Innate and Adaptive Responses Restores Immune Surveillance and Establishes Antitumor Immunologic Memory16
Dual Chimeric Antigen Receptor T Cells Targeting CD38 and SLAMF7 with Independent Signaling Demonstrate Preclinical Efficacy and Safety in Multiple Myeloma15
Long-Read Sequencing Reveals Alternative Splicing-Driven, Shared Immunogenic Neoepitopes Regardless of SF3B1 Status in Uveal Melanoma15
Insights into Immune Escape During Tumor Evolution and Response to Immunotherapy Using a Rat Model of Breast Cancer15
Distinct spatially resolved tumor microenvironment trajectories define benefit from ramucirumab plus pembrolizumab in refractory PD-L1+ gastric cancer15
Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer15
CD73 Inhibits cGAS–STING and Cooperates with CD39 to Promote Pancreatic Cancer15
Antigen Priming Induces Functional Reprogramming in iNKT Cells via Metabolic and Epigenetic Regulation: An Insight into iNKT Cell-Based Antitumor Immunotherapy15
The Conventional Dendritic Cell 1 Subset Primes CD8+ T Cells and Traffics Tumor Antigen to Drive Antitumor Immunity in the Brain15
Low Serum Apolipoprotein A1 Levels Impair Antitumor Immunity of CD8+ T Cells via the HIF-1α–Glycolysis Pathway15
Small Gene Networks Delineate Immune Cell States and Characterize Immunotherapy Response in Melanoma14
TIME for Endometrial Cancer: Advancements and Challenges in Therapeutic Targets for the Endometrial Cancer Tumor Immune Microenvironment14
About the Rising Star14
Let the Guard Down: cAMP Activators Can Improve Immunotherapy in GBM14
Combination of Anti–PD-1 and Electroacupuncture Induces a Potent Antitumor Immune Response in Microsatellite-Stable Colorectal Cancer14
ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade14
Abstract P062: PI3Kγδ inhibitor plus radiation enhances the antitumor immune effect of PD-1 blockade in syngenic murine breast cancer and humanized patient-derived xenograft model14
The Problem with Syngeneic Mouse Tumor Models14
Sequential Exposure to IL21 and IL15 During Human Natural Killer Cell Expansion Optimizes Yield and Function14
Accounting for B-cell Behavior and Sampling Bias Predicts Anti–PD-L1 Response in Bladder Cancer14
PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy14
Abstract IA16: Immune suppression in cancer and strategies for its reversal14
The Dark Knight: Functional Reprogramming of Neutrophils in the Pathogenesis of Colitis-Associated Cancer13
A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors13
Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer13
TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids13
Abstract A005: TAZ-TEAD signaling alters the immune microenvironment of cutaneous melanoma13
Chronic ISG15 Exposure Accelerates CD8+ T-cell Dysfunction while Increasing PD-1 Blockade Sensitivity in Oral Squamous Cell Carcinoma13
The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy13
A Sampling of Highlights from the Literature13
Unlocking the Immune Response in ALK-Rearranged Lung Adenocarcinoma13
Abstract A015: The emerging role of basophils in non-muscle-invasive bladder cancer13
Tertiary Lymphoid Structures Are Associated with Enhanced Macrophage Activation and Immune Checkpoint Expression and Predict Outcome in Cervical Cancer13
Efficacy and Synergy with Cisplatin of an Adenovirus Vectored Therapeutic E1E2E6E7 Vaccine against HPV Genome–Positive C3 Cancers in Mice13
A Sampling of Highlights from the Literature12
Abstract IA08: Development and use of Engineered Regulatory T cells to treat Autoimmune Diseases12
Interactions between MDSCs and the Autonomic Nervous System: Opportunities and Challenges in Cancer Neuroscience12
Abstract PR-15: Neuroimmune dysregulation in ovarian cancer: the role of chronic stress on microglial activation and systemic inflammation12
Abstract A023: Myeloid checkpoint blockade potentiates radiotherapy by modulating dendritic cells and reducing Treg-driven immunosuppression12
Abstract B027: iSIGN panel identifies germ cell tumors via whole-proteome phage immunoprecipitation sequencing12
Host Tissue Factors Predict Immune Surveillance and Therapeutic Outcomes in Gastric Cancer12
Something Old and Something New to Unleash the Power of Natural Killer Cells against Metastases12
Abstract A006: Assessment of EBV DNA methylation to guide antiviral use in EBV-associated lymphoma12
Abstract A017: Neutrophil extracellular traps reprogram macrophages to an immunosuppressive phenotype in non-small-cell lung cancer12
High-Dimensional Analyses Reveal IL15 Enhances Activation of Sipuleucel-T Lymphocyte Subsets and Reverses Immunoresistance12
IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status12
Targeting Cancer-Associated Glycosylation for Adoptive T-cell Therapy of Solid Tumors11
Abstract A004: Modulating chromatin remodeling as a strategy to reverse immune evasion in ovarian cancer11
Tyrosine Kinase Inhibition Activates Intratumoral γδ T Cells in Gastrointestinal Stromal Tumor11
Mesenchymal Stem Cells and Fibroblasts Contribute to Microvascular Proliferation in Glioblastoma and are Correlated with Immunosuppression and Poor Outcome11
Abstract PR-12: Single-cell profiling of tumor-infiltrating B cells reveals autoantibody repertoires and potential cross-talk with T cells11
A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors11
Effective Treatment of Established Bone Metastases Can Be Achieved by Combinatorial Osteoclast Blockade and Depletion of Granulocytic Subsets11
Abstract P076: Humanized anti-αvβ3 antibody engineered to selectively promote macrophage-mediated cancer cell death11
Gastric Microbiome Alterations Are Associated with Decreased CD8+ Tissue-Resident Memory T Cells in the Tumor Microenvironment of Gastric Cancer11
Abstract P068: Automated cell type specific PD-L1 quantification by artificial intelligence using high throughput bleach & stain 15-marker multiplex fluorescence immunohistochemistry in human canc11
Abstract B004: Route dependent T-cell activation by mRNA cluster therapies11
Abstract A003: Identification of immunomodulatory compounds by high-throughput proteomics: Insights from quantification of 1000 proteins in a 20,000 sample screen11
iBRIDGE: A Data Integration Method to Identify Inflamed Tumors from Single-cell RNA-Seq Data and Differentiate Cell Type–Specific Markers of Immune-Cell Infiltration11
Abstract P051: Function of shp-1 and shp-2 phosphatases in T cell-mediated anti-tumor response11
Abstract B021: Multi-functional telodendrimer nanodrug: Nanocarrier for ovarian cancer treatment and immunomodulator to control inflammation and sensitize the tumor11
0.2146999835968